Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Beova granted marketing approval in Japan for overactive bladder

Sep. 25, 2018

ASTRID study of enobosarm does not achieve statistical significance on the primary endpoint

Sep. 25, 2018

TAS-303 shows potential as a novel therapeutic agent for stress urinary incontinence

Sep. 20, 2018

Sanofi achieves KEAP1/Nrf2 inhibition with bioavailable small molecules

Sep. 19, 2018

Patient recruitment starts in two phase II trials of DMX-200 in kidney disease

Sep. 18, 2018

Humanized midkine antibody demonstrates efficacy in experimental model of FSGS

Sep. 13, 2018

SuPAR predicts chronic kidney disease progression in Black Americans

Sep. 12, 2018

Daiichi Sankyo discovers bacterial tryptophanase inhibitors

Sep. 10, 2018

BAY-1101042, a potent NO- and heme-independent sGC activator suitable for oral dosing

Sep. 5, 2018

Janssen Pharmaceutica NV synthesizes 5-HT2B receptor antagonists

Sep. 4, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Wuxi Apptec insists it’s ‘not a Chinese military company’
BioWorld
Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.